Literature DB >> 28154020

Comparison of Performance of Improved Serum Estimators of Glomerular Filtration Rate (GFR) to 99mTc-DTPA GFR Methods in Patients with Hepatic Cirrhosis.

Zaid Haddadin1, Vivian Lee2, Christopher Conlin2, Lei Zhang2, Kristi Carlston2, Glen Morrell2, Daniel Kim3, John M Hoffman2, Kathryn Morton4.   

Abstract

Glomerular filtration rate (GFR) measurements are critical in patients with hepatic cirrhosis but potentially erroneous when based on serum creatinine. New equations for estimated GFR (eGFR) have shown variable performance in cirrhotics, possibly because of inaccuracies in reference methods for measured GFR (mGFR). The primary objective was to compare the performance of 4 improved eGFR equations with a 1-compartment, 2-sample plasma slope intercept 99mTc-DTPA mGFR method to determine whether any of the eGFR calculations could replace plasma 99mTc-DTPA mGFR in patients with cirrhosis. The secondary objective was to test the hypothesis that mGFR using voluntary voided urine collections introduces error compared with plasma-only methods.
Methods: Fifty-four patients with hepatic cirrhosis underwent mGFR determinations from 2 plasma samples at 1 and 3 h after intravenous administration of 185 MBq of 99mTc-DTPA. GFR was also generated by a UV/P calculation derived from blood and urine samples. These mGFRs were compared with the eGFRs generated by 4 estimating equations: MDRD (Modified Diet in Renal Disease), CKD-EPI (Chronic Kidney Disease-Epidemiology Collaboration) (serum creatinine [SCr]), CKD-EPI (cystatin [CysC]), and CKD-EPI (CysC+SCr). eGFRs were compared with mGFRs by Pearson correlation, precision, bias, percentage bias, and accuracy (eGFRs varying by <10% [p10], <20% [p20] or <30% [p30] from the corresponding mGFR).
Results: All eGFRs showed poorer performance when the UV/P 99mTc-DTPA mGFR was used as the reference than when the plasma 99mTc-DTPA mGFR was used. When compared with the plasma 99mTc-DTPA mGFR method, the performance of all eGFR equations was superior to most published reports. There was a moderately good positive correlation between eGFRs and mGFRs. When compared with plasma 99mTc-DTPA mGFR, precision of eGFRs was in the range of 14-20 mL/min and showed a negligible bias. Compared with the plasma 99mTc-DTPA mGFR, CKD-EPI (CysC+SCr) showed the best overall performance and accuracy, at 85.19% (p30), 75.93% (p20), and 42.59% (p10).
Conclusion: Estimating equations for measuring eGFR performed better than in most published reports, attributable to use of the plasma 99mTc-DTPA mGFR method as a reference. CKD-EPI (CysC+SCr) eGFR showed the best overall performance. However, more discriminating methods may be required when accurate GFR measurements are necessary. mGFR measurements using urine collections may introduce error compared with plasma-only methods.
© 2017 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  99mTc-DTPA; CKD-EPI; Cr; GFR; MDRD; cirrhosis; creatinine; glomerular filtration rate

Mesh:

Substances:

Year:  2017        PMID: 28154020      PMCID: PMC5370293          DOI: 10.2967/jnmt.116.180851

Source DB:  PubMed          Journal:  J Nucl Med Technol        ISSN: 0091-4916


  28 in total

1.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors: 
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

2.  Creatinine Versus Cystatin C for Estimating GFR in Patients With Liver Cirrhosis.

Authors:  Aldo Torre; Jonathan Manuel Aguirre-Valadez; José Manuel Arreola-Guerra; Octavio René García-Flores; Ignacio García-Juárez; Cristino Cruz-Rivera; Ricardo Correa-Rotter; José Antonio Niño-Cruz
Journal:  Am J Kidney Dis       Date:  2015-10-31       Impact factor: 8.860

3.  Report of the Radionuclides in Nephrourology Committee on renal clearance.

Authors:  M D Blaufox; M Aurell; B Bubeck; E Fommei; A Piepsz; C Russell; A Taylor; H S Thomsen; D Volterrani
Journal:  J Nucl Med       Date:  1996-11       Impact factor: 10.057

Review 4.  Acute variceal bleeding.

Authors:  Juan Carlos García-Pagán; Enric Reverter; Juan G Abraldes; Jaime Bosch
Journal:  Semin Respir Crit Care Med       Date:  2012-03-23       Impact factor: 3.119

5.  Liver Cirrhosis and Kidney.

Authors:  Alexander L Gerbes
Journal:  Dig Dis       Date:  2016-05-11       Impact factor: 2.404

6.  Estimating glomerular filtration rate from serum creatinine and cystatin C.

Authors:  Lesley A Inker; Christopher H Schmid; Hocine Tighiouart; John H Eckfeldt; Harold I Feldman; Tom Greene; John W Kusek; Jane Manzi; Frederick Van Lente; Yaping Lucy Zhang; Josef Coresh; Andrew S Levey
Journal:  N Engl J Med       Date:  2012-07-05       Impact factor: 91.245

Review 7.  Renal failure and cirrhosis: a systematic review of mortality and prognosis.

Authors:  Giuseppe Fede; Gennaro D'Amico; Vasiliki Arvaniti; Emmanuel Tsochatzis; Giacomo Germani; Dimosthenis Georgiadis; Alberto Morabito; Andrew Kenneth Burroughs
Journal:  J Hepatol       Date:  2011-12-13       Impact factor: 25.083

8.  Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults.

Authors:  G B Haycock; G J Schwartz; D H Wisotsky
Journal:  J Pediatr       Date:  1978-07       Impact factor: 4.406

9.  Effect of clinical variables and immunosuppression on serum cystatin C and beta-trace protein in kidney transplant recipients.

Authors:  Christine A White; Ayub Akbari; Steve Doucette; Dean Fergusson; Tim Ramsay; Naser Hussain; Laurent Dinh; Guido Filler; Nathalie Lepage; Greg A Knoll
Journal:  Am J Kidney Dis       Date:  2009-07-19       Impact factor: 8.860

10.  Time Varying Apparent Volume of Distribution and Drug Half-Lives Following Intravenous Bolus Injections.

Authors:  Carl A Wesolowski; Michal J Wesolowski; Paul S Babyn; Surajith N Wanasundara
Journal:  PLoS One       Date:  2016-07-12       Impact factor: 3.240

View more
  1 in total

Review 1.  Methods of Estimating Kidney Function for Drug Dosing in Special Populations.

Authors:  Laura A Hart; Gail D Anderson
Journal:  Clin Pharmacokinet       Date:  2018-08       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.